Dehydroepiandrosterone (DHEA) and aging

Archives of Gerontology and Geriatrics

Volumn 24, Issue 3, 1997, Pages 233-241

  Barrou, Zina ^a   Charru, Philippe ^a   Lidy, Claude ^a  

^a HÔPITAL FERNAND WIDAL   (France)

Author keywords

Aging; Dehydroepiandrosterone; Dehydroepiandrosterone sulfate

Indexed keywords

LIPID; PRASTERONE; STEROID; SULFATASE;

ADRENAL GLAND; AGING; BODY COMPOSITION; BODY WEIGHT; CANCER; COGNITIVE DEFECT; HORMONE SUBSTITUTION; HUMAN; IMMUNE DEFICIENCY; INSULIN TOLERANCE TEST; ISCHEMIC HEART DISEASE; NONHUMAN; OSTEOPOROSIS; PRIMATE; PRIORITY JOURNAL; REVIEW; STEROID BLOOD LEVEL; STEROID RELEASE; WELLBEING;

EID: 0030933507     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4943(96)00761-3     Document Type: Review

References (47)

1. Araneo, B. and Daynes, R. (1995): Dehydroepiandrosterone functions more than an antiglucocorticoid in preserving immunocompetence after thermal injury. Endocrinology, 136, 393-401.
2. Araneo, B.A., Woods, M.L. and Daynes, R.A. (1993): Reversal of the immunosenescent phenotype by dehydroepiandrosterone: hormone treatment provides an adjuvant effect on the immunization of aged mice with recombinant hepatitis B antigen. J. Infect. Dis., 167, 830-840.
3. Barrett-Connor, E. and Edelstein, S.L. (1994): A prospective study of dehydroepiandrosterone sulfate and cognitive function in an older population: the Rancho Bernardo study. J. Am. Geriatr. Soc., 42, 420-423.
4. Barrett-Connor, E. and Goodman-Gruen, D. (1995): Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo study. Circulation, 91, 1757-1760.
5. Barrett-Connor, E., Khaw, K.T. and Yen, S. (1986): A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N. Engl. J. Med., 315, 1519-1524.
6. Barrett-Connor, E., Friedlander, N.J. and Khaw, K.T. (1990): Dehydroepiandrosterone sulfate and breast cancer risk. Cancer Res., 50, 6571-6574.
7. Barrett-Connor, E., Silverstein, D.K. and Edelstein, S.L. (1993): A prospective study of dehydroepiandrosterone sulfate (DHEAS) and bone mineral density in older men and women. Am. J. Epidemiol., 137, 201-206.
8. Baulieu, E.E. (1995): Studies on dehydroepiandrosterone (DHEA) and its sulphate during aging, C. R. Acad. Sci. Paris., 318, 7-11.
9. Baulieu, E.E. and Robel, P. (1990): Neurosteroids: a new brain function? J. Steroid Biochem. Mol. Biol., 37, 395-403.
10. Beer, N.A., Jakubowicz, D.J., Beer, R.M. and Nestler, J.E. (1994): Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate levels in obese hypertensive men and women. J. Clin. Endocrinol. Metab., 79, 1077-1081.
11. Bélanger, A., Candas, B., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L. and Labrie, F. (1994): Changes in serum concentrations of conjugated and unconjugated steroids in 40-to 80-year old men. J. Clin. Endocrinol. Metab., 79, 1086-1090.
12. Birkenhäger-Gillesse, E.G., Derksen, J. and Lagaay, A.M. (1994): Dehydroepiandrosterone sulphate (DHEAS) in the oldest old, aged 85 and over. Ann N.Y. Acad, Sci., 719, 543-552.
13. Casson, P.R., Faquin, L.C. and Stentz, F.B. (1995): Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil. Steril., 63, 1027-1031.
14. Coleman, D.L., Schwizer, R.W. and Leiter, E.H. (1983): Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and in aged normal mice. Diabetes, 33, 26-32.
15. Demirgören, S., Majewska, M.D., Spivak, C.E. and London, E.D. (1991): Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABA receptor. Neuroscience, 45, 127-135.
16. Diamond, M.P., Grainger, D.A., Laudano, A.J., Starick-zych, K. and DeFronzo, R.A. (1991): Effect of acute physiological elevations of insulin on circulating androgen levels in nonobese women. J. Clin. Endocrinol. Metab., 72, 883-887.
17. Eich, D.M., Nestler, J.E., Johnson, D.E., Dworkin, G.H., Daijin, K., Wechsler, A.S. and Hess, M.L. (1993): Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation, 87, 261-269.
18. Gordon, G.B., Bush, D.E. and Weisman, H.F. (1988): Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimai injury. J. Clin. Invest., 82, 712-720.
19. Hubert, G.D., Schriock, E.D., Givens, J.R. and Buster, J.E. (1991): Suppression of circulating Δ4 androstenedione and dehydroepiandrosterone sulfate during oral glucose tolerance test in normal females. J. Clin. Endocrinol. Metab., 73, 781-784.
20. Kurzman, I.D., MacEwen, E.G. and Haffa, A.L. (1989): Reduction in body weight and cholesterol in spontaneously obese dogs by dehydroepiandrosterone. Int. J. Obesity, 14, 95-104.
21. LaCroix, A.Z., Yano, K. and Reed, D.M. (1992): Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation, 86, 1529-1535.
22. Leblhuber, F., Neubauer, C., Peichl, M., Reisecker, F., Steinparz, F.X., Winhager, E. and Dienstl, E. (1993): Age and sex differences of dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels in normal controls and Alzheimer's disease (AD). Psychopharmacology, 11, 23-26.
23. Morales, A.J., Nolan, J.J., Nelson, J.C. and Yen, S.S. (1994): Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab., 78, 1360-1367.
24. Mortola, J.F. and Yen, S.S. (1990): The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in post-menopausal women. J. Clin. Endocrinol. Metab., 71, 696-704.
25. Näsman, B., Olsson, T., Bäckström, T., Erikson, S., Grankvist, K., Viitanen, M. and Bucht, G. (1991): Serum dehydroepiandrosterone sulfate in Alzheimer's disease and in multi-infarct dementia. Biol. Psychiatry, 30, 684-690.
26. Nestler, J.E., Barlascini, C.O., Clore, J.N. and Blackard, W.G. (1988): Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J. Clin. Endocrinol. Metab., 66, 57-61.
27. Nestler, J.E., Usiskin, K.S., Barlascini, CO., Welty, D.F., Clore, J.N. and Blackard, W.G. (1989): Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms. J. Clin. Endocrinol. Metab., 69, 1040-1046.
28. Nestler, J.E., Clore, J.N. and Blackard, W.G. (1992): Dehydroepiandrosterone: the 'missing link' between hyperinsulinemia and atherosclerosis? FASEB J., 6, 3073-3075.
29. Nestler, J.E., Beer, N.A., Jakubowicz, D.J. and Beer, R.M. (1994): Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J. Clin. Endocrinol. Metab., 78, 549-554.
30. Nestler, J.E., Beer, N.A., Jakubowikz, D.J., Colombo, C. and Beer, R.M. (1995): Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men. J. Clin. Endocrinol. Metab., 80, 700-706.
31. Orentreich, N., Brind, J.L., Rizer, R.L. and Vogelman, J.H. (1984): Age and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulhood. J. Clin. Endocrinol. Metab., 59, 551-555.
32. Orentreich, N., Brind, J.L., Vogelman, J.H., Andres, R. and Baldwin, H. (1992): Long term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J. Clin. Endocrinol. Metab., 75, 1002-1004.
33. Parker, L.N., Levin, E.R. and Lifrak, E.T. (1985): Evidence for adrenocortical adaptation to severe illness. J. Clin. Endocrinol. Metab., 60, 947-952.
34. Pavlov, E.P., Harman, S.M., Chrousos, G.P., Loriaux, D.L. and Blackman, M.R. (1986): Responses of plasma adrenocorticotropin, cortisol, and dehydroepiandrosterone to ovine corticotropin-releasing hormone in healthy aging men. J. Clin. Endocrinol, Metab., 62, 767-772.
35. Rao, M.S., Subbarao, V., Yeldandi, A.V. and Reddy, J.K. (1992): Hepatocarcinogenicity of dehydroepiandrosterone in the rat. Cancer Res., 52, 2977-2979.
36. Ravaglia, G., Forti P., Maioli, F., Boschi, F., Bernardi, M., Pratelli, L., Pizzoferrato, A. and Gasbarrini, G. (1996): The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an italian study on healthy free-living over-ninety-year-olds. J. Clin. Endocrinol. Metab., 81, 1173-1178.
37. Regelson, W. and Kalimi, M. (1994): Dehydroepiandrosterone (DHEA) - the multifunctional steroid. II. Effects on the CNS, cell proliferation, metabolic and vascular, clinical and other effects. Mechanism of action? Ann. N.Y. Acad. Sci., 719, 564-575.
38. Regelson, W., Loria, R. and Kalimi, M. (1994): Dehydroepiandrosterone (DHEA) the 'mother steroid'. I. Immunologic action. Ann. N.Y. Acad. Sci., 719, 553-563.
39. Roberts, E., Bologa, L., Flood, J.F. and Smith, G.E. (1987): Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice. Brain Res., 40, 357-362.
40. Rozenberg, S., Ham, H. and Bosson, D. (1990): Age, steroids and bone mineral content. Maturitas, 12, 137-143.
41. Spector, T.D., Thompson, P.W., Perry, L.A., McGarrigle, H.H. and Edwards, A.C. (1991): The relationship between sex steroids and bone mineral content in women soon after menopause. Clin. Endocrinol., 34, 37-41.
42. Steinberg, K.K., Freni-Titulaer, L.W. and De Puey, E.G. (1989): Sex steroids and bone density in premenopausal and perimenopausal women. J. Clin. Endocrinol. Metab., 69, 533-539.
43. Sunderland, T., Merril, C.R., Harrington, M.G., Lawlor, B.A., Molchan, S.E., Martinez, R. and Murphy, D.L. (1989): Reduced plasma dehydroepiandrosterone concentrations in alzheimer's disease. Lancet, 2, 570.
44. Thomas, G., Frenoy, N., Legrain, S., Sebag-Lanoe, R., Baulieu, E.E. and Debuire, B. (1994): Serum dehydroepiandrosterone sulfate levels as an individual marker. J. Clin. Endocrinol. Metab., 79, 1273-1276.
45. Welle, S., Jozefowicz, R. and Statt, M. (1990): Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. J. Clin. Endocrinol. Metab., 71, 1259-1264.
46. Young, J., Corpechot, C., Haug, M., Gobaille, S., Baulieu, E.E. and Robel, P. (1991): Suppressive effects of dehydroepiandrosterone and 3b-methyl-androst-5-en-17-one on attack towards lactating female intruders by castrated male mice. II. Brain steroids. Biochem. Biophys. Res. Commun., 174, 892-897.
47. Zumoff, B., Levin, J., Rosenfeld, R.S., Markham, M., Strain, G.W. and Fukushima, D.K. (1981): Abnormal 24 hour mean plasma concentrations dehydroepiandrosterone and dehydroepiandrosterone sulfate in women with primary operable breast cancer. Cancer Res., 41, 3360-3363.